Abiopharma

New Form 6-K - SciSparc Ltd. Filed: 2025-07-31 AccNo: 0001213900-25-069979 Size: 55 KB

New Form NT 20-F - Akso Health Group Filed: 2025-07-31 AccNo: 0001213900-25-069980 Size: 22 KB

New Form 8-K - RESMED INC Filed: 2025-07-31 AccNo: 0001193125-25-170512 Size: 450 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 424B5 - ADIAL PHARMACEUTICALS, INC. Filed: 2025-07-31 AccNo: 0001213900-25-069975 Size: 14 KB

New Form PRE 14A - Processa Pharmaceuticals, Inc. Filed: 2025-07-31 AccNo: 0001493152-25-011519 Size: 509 KB

iSpecimen Inc. Announces Pricing of Approximately $1.75 Million Private Placement Priced At-the-Market

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

Guardant Health, Inc. - Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference

ATEC - ATEC Reports Second Quarter 2025 Financial Results and Raises Full-Year Guidance

New Form SCHEDULE 13D/A - Abivax S.A. Filed: 2025-07-31 AccNo: 0001104659-25-072677 Size: 25 KB

New Form 4 - Cardiff Oncology, Inc. Filed: 2025-07-31 AccNo: 0000950170-25-100882 Size: 6 KB

New Form 4 - GeneDx Holdings Corp. Filed: 2025-07-31 AccNo: 0001415889-25-020713 Size: 9 KB

P3 Health Partners Schedules Second Quarter 2025 Earnings Release and Conference Call

Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update